Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics Analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi:10.1016/S0140-6736(18)32552-230910306
   PubMed Web of Science ®Google Scholar
• Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth ovarian cancer consensus conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28(4):727–732. doi:10.1093/annonc/mdw66327993805
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437–2448. doi:10.1200/JCO.19.0019431403868
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.38421892204
   PubMed Web of Science ®Google Scholar
• Freimund AE, Beach JA, Christie EL, Bowtell DDL. Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):983–996. doi:10.1016/j.hoc.2018.07.00730390769
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C. Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity. Expert Opin Pharmacother. 2013;14(13):1839–1857. doi:10.1517/14656566.2013.81393423876094
   PubMed Web of Science ®Google Scholar
• Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20:17.
   Web of Science ®Google Scholar
• Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.27558151
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, He Q-Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.011822455463
   PubMed Web of Science ®Google Scholar
• Blanco G. Na, K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation. Semin Nephrol. 2005;25(5):292–303. doi:10.1016/j.semnephrol.2005.03.00416139684
   PubMed Web of Science ®Google Scholar
• Kaplan JH. Biochemistry of Na, K-ATPase. Annu Rev Biochem. 2002;71:511–535. doi:10.1146/annurev.biochem.71.102201.14121812045105
   PubMed Web of Science ®Google Scholar
• Shiratori O. Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells: in vitro and in vivo studies. Gann. 1967;58:521–528.5589524
   PubMedGoogle Scholar
• Bejcek J, Spiwok V, Kmonickova E, Rimpelova S. Na+/K+-ATPase revisited: on its mechanism of action, role in cancer, and activity modulation. Molecules. 2021;26(7):1905. doi:10.3390/molecules2607190533800655
   PubMed Web of Science ®Google Scholar
• Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov. 2008;7(11):926–935. doi:10.1038/nrd268218948999
   PubMed Web of Science ®Google Scholar
• Huang W, Zhang Y, Xu Y, et al. Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma. Cancer Cell Int. 2020;20(309). doi:10.1186/s12935-020-01414-5
   Web of Science ®Google Scholar
• Chen WL, Ren Y, Ren J, et al. (+)-strebloside-induced cytotoxicity in ovarian cancer cells is mediated through cardiac glycoside signaling networks. J Nat Prod. 2017;80(3):659–669. doi:10.1021/acs.jnatprod.6b0115028234008
   PubMed Web of Science ®Google Scholar
• Tummala R, Wolle D, Barwe SP, Sampson VB, Rajasekaran AK, Pendyala L. Expression of Na, K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin. Cancer Chemother Pharmacol. 2009;64(6):1187–1194. doi:10.1007/s00280-009-0985-x19322565
   PubMed Web of Science ®Google Scholar
• Venetucci L, Denegri M, Napolitano C, Priori SG. Inherited calcium channelopathies in the pathophysiology of arrhythmias. Nat Rev Cardiol. 2012;9(10):561–575. doi:10.1038/nrcardio.2012.9322733215
   PubMed Web of Science ®Google Scholar
• Schmidt S, Liu G, Liu G, et al. Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells. Oncotarget. 2014;5(13):4799–4810. doi:10.18632/oncotarget.203525015419
   PubMedGoogle Scholar
• Pelzl L, Hosseinzadeh Z, Alzoubi K, et al. Impact of Na+/Ca2+ exchangers on therapy resistance of ovary carcinoma cells. Cell Physiol Biochem. 2015;37(5):1857–1868. doi:10.1159/00043854726584285
   PubMedGoogle Scholar
• Taylor JT, Zeng XB, Pottle JE, et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol. 2008;14(32):4984–4991. doi:10.3748/wjg.14.498418763278
   PubMed Web of Science ®Google Scholar
• Steinhardt RA, Alderton J. Intracellular free calcium rise triggers nuclear envelope breakdown in the sea urchin embryo. Nature. 1988;332(6162):364–366. doi:10.1038/332364a03127727
   PubMed Web of Science ®Google Scholar
• Parkash J, Asotra K. Calcium wave signaling in cancer cells. Life Sci. 2010;87(19–22):587–595. doi:10.1016/j.lfs.2010.09.01320875431
   PubMed Web of Science ®Google Scholar
• Heise N, Palme D, Misovic M, et al. Non-selective cation channel-mediated Ca2+-entry and activation of Ca2+/calmodulin-dependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. Cell Physiol Biochem. 2010;26(4–5):597. doi:10.1159/00032232721063097
   PubMedGoogle Scholar
• Lee H, Kim JW, Kim DK, et al. Calcium channels as novel therapeutic targets for ovarian cancer stem cells. Int J Mol Sci. 2020;21(7):2327.
   PubMed Web of Science ®Google Scholar
• Davis FM, Parsonage MT, Cabot PJ, et al. Assessment of gene expression of intracellular calcium channels, pumps and exchangers with epidermal growth factor-induced epithelial-mesenchymal transition in a breast cancer cell line. Cancer Cell Int. 2013;13(1):76. doi:10.1186/1475-2867-13-7623890218
   PubMed Web of Science ®Google Scholar
• Abdul M, Ramlal S, Hoosein N. Ryanodine receptor expression correlates with tumor grade in breast cancer. Pathol Oncol Res. 2008;14(2):157–160. doi:10.1007/s12253-008-9045-918431693
   PubMed Web of Science ®Google Scholar
• Lu H, Chen I, Shimoda LA, et al. Chemotherapy-induced Ca(2+) release stimulates breast cancer stem cell enrichment. Cell Rep. 2017;18(8):1946–1957. doi:10.1016/j.celrep.2017.02.00128228260
   PubMed Web of Science ®Google Scholar
• Otto Warburg FW, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530. doi:10.1085/jgp.8.6.51919872213
   PubMedGoogle Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.30913298683
   PubMed Web of Science ®Google Scholar
• Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers. 2018;10(9):337. doi:10.3390/cancers10090337
   PubMed Web of Science ®Google Scholar
• Dar S, Chhina J, Mert I, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells. Sci Rep. 2017;7(1):8760. doi:10.1038/s41598-017-09206-028821788
   PubMed Web of Science ®Google Scholar
• Ricci F, Brunelli L, Affatato R, et al. Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts. Ther Adv Med Oncol. 2019;11:1758835919839543. doi:10.1177/175883591983954331258626
   PubMed Web of Science ®Google Scholar
• Gentric G, Kieffer Y, Mieulet V, et al. PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 2019;29(1):156–173 e110. doi:10.1016/j.cmet.2018.09.00230244973
   PubMed Web of Science ®Google Scholar
• Yang M, Liu P, Huang P. Cancer stem cells, metabolism, and therapeutic significance. Tumour Biol. 2016;37(5):5735–5742. doi:10.1007/s13277-016-4945-x26864589
   PubMedGoogle Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–737. doi:10.1038/nm0797-7309212098
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–115. doi:10.1038/nature0538417122771
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–3988. doi:10.1073/pnas.053029110012629218
   PubMed Web of Science ®Google Scholar
• Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer. 2006;42(9):1213–1218. doi:10.1016/j.ejca.2006.01.03716632344
   PubMed Web of Science ®Google Scholar
• Wilson RJ, Thomas CD, Fox R, Roy DB, Kunin WE. Spatial patterns in species distributions reveal biodiversity change. Nature. 2004;432(7015):393–396. doi:10.1038/nature0303115549106
   PubMed Web of Science ®Google Scholar
• Li SS, Ma J, Wong AST. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. J Gynecol Oncol. 2018;29(2):e32. doi:10.3802/jgo.2018.29.e3229468856
   PubMed Web of Science ®Google Scholar
• Pastò A 1, Bellio C 1, Pilotto G 1, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5(12):4305–4319. doi:10.18632/oncotarget.201024946808
   PubMedGoogle Scholar
• Deleyto-Seldas N, Efeyan A. The mTOR-autophagy axis and the control of metabolism. Front Cell Dev Biol. 2021;9:655731. doi:10.3389/fcell.2021.65573134277603
   PubMed Web of Science ®Google Scholar
• de la Cruz Lopez KG, Toledo Guzman ME, Sanchez EO, Garcia Carranca A. mTORC1 as a regulator of mitochondrial functions and a therapeutic target in cancer. Front Oncol. 2019;9:1373. doi:10.3389/fonc.2019.0137331921637
   PubMed Web of Science ®Google Scholar
• Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450(7170):736–740. doi:10.1038/nature0632218046414
   PubMed Web of Science ®Google Scholar
• Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L. Cellular mechanism of gene mutations and potential therapeutic targets in ovarian cancer. Cancer Manag Res. 2021;13:3081–3100. doi:10.2147/CMAR.S29299233854378
   PubMedGoogle Scholar
• Martinez-Outschoorn UE, Curry JM, Ko YH, et al. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFkappaB target stromal MCT4. Cell Cycle. 2013;12(16):2580–2597. doi:10.4161/cc.2551023860378
   PubMed Web of Science ®Google Scholar